Supplemental Protocol S1

Protocol to design and clone amiRNAs or syn-tasiRNAs in *BsaI/ccd*B-based ('B/c') vectors containing *AtMIR390a* or *AtTAS1c* precursors, respectively.

INDEX

- 1. Selection of the amiRNA or syn-tasiRNA(s) sequence(s)
- 2. Design of amiRNA or syn-tasiRNA oligonucleotides
- 2.1 Design of amiRNA oligonucleotides
- 2.1.1 Sequence of the AtMIR390a cassette containing the amiRNA
- 2.1.2. Sequence of the amiRNA oligonucleotides
- 2.2 Design of syn-tasiRNA oligonucleotides
- 2.2.1 Sequence of the AtTAS1c cassette containing the syn-tasiRNA(s)
- 2.2.2. Sequence of the syn-tasiRNA oligonucleotides
- 3. Cloning of the amiRNA/syn-tasiRNA sequences in BsaI/ccdB (B/c) vectors
- 3.1 Oligonucleotide annealing
- 3.2. Digestion-ligation reaction
- 3.3. E.coli transformation and analysis of transformants

1. Selection of the amiRNA or syn-tasiRNA(s) sequence(s)

A link to a web tool for automated design of the amiRNA or syn-tasiRNA sequence(s) will be available at http://p-sams.carringtonlab.org/

2. Design of amiRNA or syn-tasiRNA oligonucleotides

A link to a web tool for automated design of the amiRNA or syn-tasiRNA oligonucleotide sequences will be available at http://p-sams.carringtonlab.org/

2.1 Design of amiRNA oligonucleotides

2.1.1 Sequence of the AtMIR390a cassette containing the amiRNA

The following FASTA sequence includes the amiRNA sequence inserted in the *AtMIR390a* precursor sequence:

>amiRNA in AtMIR390a precursor

Where:

- -X is a DNA base of the amiRNA sequence, and the subscript number is the base position in the amiRNA 21-mer
- -X is a DNA base of the amiRNA* sequence, and the subscript number is the base position in the amiRNA* 21-mer
- -X is a DNA base of the AtMIR390a foldback
- $-\underline{\mathbf{X}}$ is a DNA base of the *AtMIR390a* foldback included in the oligonucleotides required to clone the amiRNA insert in B/c vectors
- -X is a DNA base of the *AtMIR390a* foldback that may be modified to preserve the authentic *AtMIR390a* duplex structure

-X is a DNA base of the AtMIR390a precursor

In the sequence above:

-Insert the amiRNA sequence where you see

$$\boldsymbol{X}_{1} \boldsymbol{X}_{2} \boldsymbol{X}_{3} \boldsymbol{X}_{4} \boldsymbol{X}_{5} \boldsymbol{X}_{6} \boldsymbol{X}_{7} \boldsymbol{X}_{8} \boldsymbol{X}_{9} \boldsymbol{X}_{10} \boldsymbol{X}_{11} \boldsymbol{X}_{12} \boldsymbol{X}_{13} \boldsymbol{X}_{14} \boldsymbol{X}_{15} \boldsymbol{X}_{16} \boldsymbol{X}_{17} \boldsymbol{X}_{18} \boldsymbol{X}_{19} \boldsymbol{X}_{20} \boldsymbol{X}_{21}$$

-Insert the amiRNA* sequence that has to verify the following base-pairing:

Note that:

- -In general, X_1 =T for amiRNA association with AGO1. In this case, X_{19} =A
- -Bases X_{11} and X_{9} DO NOT base-pair to preserve the central bulge of the authentic *AtMIR390a* duplex. The following base-pair rule applies:

-If
$$X_{11}=G$$
, then $X_9=A$

-If
$$X_{11}$$
=C, then X_9 =T

-If
$$X_{11}$$
=A, then X_9 =G

-If
$$X_{11}$$
=U, then X_9 =C

2.1.2. Sequence of the amiRNA oligonucleotides

The sequences of the two amiRNA oligonucleotides are:

-Forward oligonucleotide (75 b),

$$\textbf{TGTA} X_1 X_2 X_3 X_4 X_5 X_6 X_7 X_8 X_9 X_{10} X_{11} X_{12} X_{13} X_{14} X_{15} X_{16} X_{17} X_{18} X_{19} X_{20} X_{21} \\ \textbf{ATGATGATCACA}$$

$$\textbf{TTCGTTATCTATTTTT} \\ \underline{\textbf{X}_2} \\ X_1 \\ X_2 \\ X_3 \\ X_4 \\ X_5 \\ X_6 \\ X_7 \\ X_8 \\ X_9 \\ X_{10} \\ X_{11} \\ X_{12} \\ X_{13} \\ X_{14} \\ X_{15} \\ X_{16} \\ X_{17} \\ X_{18} \\ X_{19} \\ X_{$$

-Reverse oligonucleotide (75 b),

$$\textbf{AATGY}_{19} \textbf{Y}_{18} \textbf{Y}_{17} \textbf{Y}_{16} \textbf{Y}_{15} \textbf{Y}_{14} \textbf{Y}_{13} \textbf{Y}_{12} \textbf{Y}_{11} \textbf{Y}_{10} \textbf{Y}_{9} \textbf{Y}_{8} \textbf{Y}_{7} \textbf{Y}_{6} \textbf{Y}_{5} \textbf{Y}_{4} \textbf{Y}_{3} \textbf{Y}_{2} \textbf{Y}_{1} \textbf{Y}_{2} \textbf{Y}_{1} \textbf{AAAAAATGATAACG}$$

$$\textbf{AATGTGATCATY}_{21}\textbf{Y}_{20}\textbf{Y}_{19}\textbf{Y}_{18}\textbf{Y}_{17}\textbf{Y}_{16}\textbf{Y}_{15}\textbf{Y}_{14}\textbf{Y}_{13}\textbf{Y}_{12}\textbf{Y}_{11}\textbf{Y}_{10}\textbf{Y}_{9}\textbf{Y}_{8}\textbf{Y}_{7}\textbf{Y}_{6}\textbf{Y}_{5}\textbf{Y}_{4}\textbf{Y}_{3}\textbf{Y}_{2}\textbf{Y}_{1}$$

Where:

$$-\mathbf{x}_{1}\mathbf{x}_{2}\mathbf{x}_{3}\mathbf{x}_{4}\mathbf{x}_{5}\mathbf{x}_{6}\mathbf{x}_{7}\mathbf{x}_{8}\mathbf{x}_{9}\mathbf{x}_{10}\mathbf{x}_{11}\mathbf{x}_{12}\mathbf{x}_{13}\mathbf{x}_{14}\mathbf{x}_{15}\mathbf{x}_{16}\mathbf{x}_{17}\mathbf{x}_{18}\mathbf{x}_{19}\mathbf{x}_{20}\mathbf{x}_{21} = amiRNA$$

sequence

$$-\mathbf{x}_{1}\mathbf{x}_{2}\mathbf{x}_{3}\mathbf{x}_{4}\mathbf{x}_{5}\mathbf{x}_{6}\mathbf{x}_{7}\mathbf{x}_{8}\mathbf{x}_{9}\mathbf{x}_{10}\mathbf{x}_{11}\mathbf{x}_{12}\mathbf{x}_{13}\mathbf{x}_{14}\mathbf{x}_{15}\mathbf{x}_{16}\mathbf{x}_{17}\mathbf{x}_{18}\mathbf{x}_{19} \\ = partial\ amiRNA*$$

sequence

$$-\mathbf{Y}_{21}\mathbf{Y}_{20}\mathbf{Y}_{19}\mathbf{Y}_{18}\mathbf{Y}_{17}\mathbf{Y}_{16}\mathbf{Y}_{15}\mathbf{Y}_{14}\mathbf{Y}_{13}\mathbf{Y}_{12}\mathbf{Y}_{11}\mathbf{Y}_{10}\mathbf{Y}_{9}\mathbf{Y}_{8}\mathbf{Y}_{7}\mathbf{Y}_{6}\mathbf{Y}_{5}\mathbf{Y}_{4}\mathbf{Y}_{3}\mathbf{Y}_{2}\mathbf{Y}_{1} = amiRNA$$

reverse- complement sequence

 $-\mathbf{TGY}_{19}\mathbf{Y}_{18}\mathbf{Y}_{17}\mathbf{Y}_{16}\mathbf{Y}_{15}\mathbf{Y}_{14}\mathbf{Y}_{13}\mathbf{Y}_{12}\mathbf{Y}_{11}\mathbf{Y}_{10}\mathbf{Y}_{9}\mathbf{Y}_{8}\mathbf{Y}_{7}\mathbf{Y}_{6}\mathbf{Y}_{5}\mathbf{Y}_{4}\mathbf{Y}_{3}\mathbf{Y}_{2}\mathbf{Y}_{1} = amiRNA* \ reverse-complement \ sequence$

 $-X_1X_2 = AtMIR390a$ sequence that may be modified to preserve authentic AtMIR390a duplex structure.

 $-Y_2Y_1$ = reverse-complement of X_1X_2

Example:

The sequences of the two oligonucleotides to clone the amiRNA 'amiR-Trich' (TCCCATTCGATACTGCTCGCC) are:

-Sense oligonucleotide (75 b),

TGTATCCCATTCGATACTGCTCGCCATGATGATCACATTCGTTATCTATTTTTTGGCG AGCAGTCTCGAATGGGA

-Antisense oligonucleotide (75 b),

AATGTCCCATTCGAGACTGCTCGCCAAAAAATAGATAACGAATGTGATCATCATGGCG AGCAGTATCGAATGGGA

Note: the 75 b long oligonucleotides can be ordered PAGE-purified, although oligonucleotides of 'Standard Desalting' quality worked well.

2.2 Design of syn-tasiRNA oligonucleotides

2.2.1 Sequence of the AtTAS1c cassette containing the syntasiRNA(s)

The following FASTA sequence includes two syn-tasiRNA sequences inserted in the *AtTAS1c* precursor sequence:

>syn-tasiRNA-1 and syn-tasiRNA-2 in AtTAS1c

Where:

- -X is a DNA base of the syn-tasiRNA-1 sequence, and the subscript number is the base position in the syn-tasiRNA-1 21-mer
- -X is a DNA base of the syn-tasiRNA-2 sequence, and the subscript number is the base position in the syn-tasiRNA-2 21-mer
- -X is a DNA base of the *AtTAS1c* precursor included in the oligonucleotides required to clone the syn-tasiRNA insert in B/c vectors
- -X is a DNA base of the AtTAS1c precursor

Note that in general, $X_1=T$ and $X_1=T$ for syn-tasiRNA association with AGO1.

In the sequence above, replace the sequences

 $x_1x_2x_3x_4x_5x_6x_7x_8x_9x_{10}x_{11}x_{12}x_{13}x_{14}x_{15}x_{16}x_{17}x_{18}x_{19}x_{20}x_{21}$ and $x_1x_2x_3x_4x_5x_6x_7x_8x_9x_{10}x_{11}x_{12}x_{13}x_{14}x_{15}x_{16}x_{17}x_{18}x_{19}x_{20}x_{21}$ by the sequences of syntasiRNA_1 and syn-tasiRNA_2, respectively.

2.2.2. Sequence of the syn-tasiRNA oligonucleotides

The sequences of the two syn-tasiRNA oligonucleotides are:

-Sense oligonucleotide (46 b):

$$\mathbf{ATTA} \mathbf{X}_{1} \mathbf{X}_{2} \mathbf{X}_{3} \mathbf{X}_{4} \mathbf{X}_{5} \mathbf{X}_{6} \mathbf{X}_{7} \mathbf{X}_{8} \mathbf{X}_{9} \mathbf{X}_{10} \mathbf{X}_{11} \mathbf{X}_{12} \mathbf{X}_{13} \mathbf{X}_{14} \mathbf{X}_{15} \mathbf{X}_{16} \mathbf{X}_{17} \mathbf{X}_{18} \mathbf{X}_{19} \mathbf{X}_{20} \mathbf{X}_{21} \mathbf{X}_{1} \mathbf{X}_{2} \mathbf{X}_{3} \mathbf{X}_{4} \mathbf{X}_{5} \mathbf{X}_{6} \mathbf{X}_{7} \mathbf{X}_{18} \mathbf{X}_{19} \mathbf{X}_{20} \mathbf{X}_{21} \mathbf{X}_{11} \mathbf{X}_{12} \mathbf{X}_{13} \mathbf{X}_{14} \mathbf{X}_{15} \mathbf{X}_{16} \mathbf{X}_{17} \mathbf{X}_{18} \mathbf{X}_{19} \mathbf{X}_{20} \mathbf{X}_{21}$$

-Antisense oligonucleotide (46 b):

$$\begin{aligned} \mathbf{GTTCY}_{21}\mathbf{Y}_{20}\mathbf{Y}_{19}\mathbf{Y}_{18}\mathbf{Y}_{17}\mathbf{Y}_{16}\mathbf{Y}_{15}\mathbf{Y}_{14}\mathbf{Y}_{13}\mathbf{Y}_{12}\mathbf{Y}_{11}\mathbf{Y}_{10}\mathbf{Y}_{9}\mathbf{Y}_{8}\mathbf{Y}_{7}\mathbf{Y}_{6}\mathbf{Y}_{5}\mathbf{Y}_{4}\mathbf{Y}_{3}\mathbf{Y}_{2}\mathbf{Y}_{1}\mathbf{Y}_{20}\mathbf{Y}_{19}\mathbf{Y}_{18}\mathbf{Y}_{17}\\ \mathbf{Y}_{16}\mathbf{Y}_{15}\mathbf{Y}_{14}\mathbf{Y}_{13}\mathbf{Y}_{12}\mathbf{Y}_{11}\mathbf{Y}_{10}\mathbf{Y}_{9}\mathbf{Y}_{8}\mathbf{Y}_{7}\mathbf{Y}_{6}\mathbf{Y}_{5}\mathbf{Y}_{4}\mathbf{Y}_{3}\mathbf{Y}_{2}\mathbf{Y}_{1} \end{aligned}$$

Where:

 $-\mathbf{x}_{1}\mathbf{x}_{2}\mathbf{x}_{3}\mathbf{x}_{4}\mathbf{x}_{5}\mathbf{x}_{6}\mathbf{x}_{7}\mathbf{x}_{8}\mathbf{x}_{9}\mathbf{x}_{10}\mathbf{x}_{11}\mathbf{x}_{12}\mathbf{x}_{13}\mathbf{x}_{14}\mathbf{x}_{15}\mathbf{x}_{16}\mathbf{x}_{17}\mathbf{x}_{18}\mathbf{x}_{19}\mathbf{x}_{20}\mathbf{x}_{21} = \text{syn-tasiRNA-1}$ sequence $-\mathbf{x}_{1}\mathbf{x}_{2}\mathbf{x}_{3}\mathbf{x}_{4}\mathbf{x}_{5}\mathbf{x}_{6}\mathbf{x}_{7}\mathbf{x}_{8}\mathbf{x}_{9}\mathbf{x}_{10}\mathbf{x}_{11}\mathbf{x}_{12}\mathbf{x}_{13}\mathbf{x}_{14}\mathbf{x}_{15}\mathbf{x}_{16}\mathbf{x}_{17}\mathbf{x}_{18}\mathbf{x}_{19}\mathbf{x}_{20}\mathbf{x}_{21} = \text{syn-tasiRNA-2}$ sequence $-\mathbf{y}_{21}\mathbf{y}_{20}\mathbf{y}_{19}\mathbf{y}_{18}\mathbf{y}_{17}\mathbf{y}_{16}\mathbf{y}_{15}\mathbf{y}_{14}\mathbf{y}_{13}\mathbf{y}_{12}\mathbf{y}_{11}\mathbf{y}_{10}\mathbf{y}_{9}\mathbf{y}_{8}\mathbf{y}_{7}\mathbf{y}_{6}\mathbf{y}_{5}\mathbf{y}_{4}\mathbf{y}_{3}\mathbf{y}_{2}\mathbf{y}_{1} = \text{syn-tasiRNA-1}$ reverse-complement sequence

 $-\mathtt{Y}_{21} \mathtt{Y}_{20} \mathtt{Y}_{19} \mathtt{Y}_{18} \mathtt{Y}_{17} \mathtt{Y}_{16} \mathtt{Y}_{15} \mathtt{Y}_{14} \mathtt{Y}_{13} \mathtt{Y}_{12} \mathtt{Y}_{11} \mathtt{Y}_{10} \mathtt{Y}_{9} \mathtt{Y}_{8} \mathtt{Y}_{7} \mathtt{Y}_{6} \mathtt{Y}_{5} \mathtt{Y}_{4} \mathtt{Y}_{3} \mathtt{Y}_{2} \mathtt{Y}_{1} \\ = syn-tasiRNA-2$

Example

The sequences of the two oligonucleotides to clone syn-tasiRNAs 'syn-tasiR-Trich' (TCCCATTCGATACTGCTCGCC) and 'syn-tasiR-Ft' (TTGGTTATAAAGGAAGAGGCC) in positions 3'D3[+] and 3'D4[+] of *AtTAS1c*, respectively, are:
-Sense oligonucleotide (46 b):

ATTATCCCATTCGATACTGCTCGCCTTGGTTATAAAGGAAGAGGCC

-Antisense oligonucleotide (46 b):

reverse-complement sequence

GTTCGGCCTCTTCCTTTATAACCAAGGCGAGCAGTATCGAATGGGA

3. Cloning of the amiRNA/syn-tasiRNA sequences in BsaI/ccdB (B/c) vectors

Notes:

- -Available B/c vectors are listed in Table I at the end of the section.
- -AtMIR390-B/c- and AtTAS1c-B/c-based vectors must be propagated in a ccdB resistant E. coli strain such as DB3.1.
- -Alternatively, BsaI digestion of the B/c vector and subsequent ligation of the amiRNA oligonucleotide insert can be done in separate reactions

3.1. Oligonucleotide annealing

-Dilute sense oligonucleotide and antisense oligonucleotide in sterile H2O to a final concentration of $100~\mu M$.

-Prepare Oligo Annealing Buffer:

60 mM Tris-HCl (pH 7.5)

500 mM NaCl

60 mM MgCl₂

10 mM DTT

Note: Prepare 1 ml aliquots of Oligo Annealing Buffer and store at -20°C.

-Assemble the annealing reaction in a PCR tube as described below:

Forward oligonucleotide (100 µM) 2 µL

Reverse oligonucleotide (100 μ M) 2 μ L

Oligo Annealing Buffer 46 μL

Total volume 50 µL

The final concentration of each oligonucleotide is $4 \mu M$.

-Use a thermocycler to heat the annealing reaction 5 min at 94°C and then cool down (0.05°C/sec) to 20°C.

-Dilute the annealed oligonucleotides just prior to assembling the digestion-ligation reaction as described below:

Annealed oligonucleotides 3 µL

 dH_2O 37 μ L

Total volume 40 µL

The final concentration of each oligonucleotide is $0.15 \mu M$.

Note: Do not store the diluted oligonucleotides.

3.2. Digestion-ligation reaction

- Assemble the digestion-ligation reaction as described below:

B/c vector (x ug/uL)	Y μL (50 ng)
Diluted annealed oligonucleotides	1 μL
10x T4 DNA ligase buffer	1 μL
T4 DNA ligase (400 U/ μ L)	1 μL
BsaI (10U/ μ L, NEB)	1 μL
<u>dH₂O</u>	to 10 μL
Total volume	10 μL

Prepare a negative control reaction lacking BsaI.

-Mix the reactions by pipetting. Incubate the reactions at room temperature for 5 minutes at 37°C.

3.3. E.coli transformation and analysis of transformants

-Transform 1-5 ul of the digestion-ligation reaction into an *E. coli* strain that doesn't have *ccd*B resistance (e.g. DH10B, TOP10, ...) to do counter-selection.

-Pick two colonies/construct, grow LB-Kan (100 mg/ml) cultures and purify plasmids.

-Sequence with appropriate primers: M13-F (CCCAGTCACGACGTTGTAAAACGACGG) and M13-R (CAGAGCTGCCAGGAAACAGCTATGACC) for *pENTR*-based vectors, attB1 (ACAAGTTTGTACAAAAAAGCAGGCT) and attB2 (ACCACTTTGTACAAGAAAGCTGGGT) primers for *pMDC32B*-, *pMDC123SB*- or *pFK210B*-based vectors).

Vector	Small RNA class	Bacterial antibiotic resistance	Plant antibiotic resistance	GATEWAY use	Backbone	Promoter	Terminator	Plant species tested
pENTR-AtMIR390a-B/c	amiRNA	Kanamycin	-	Donor	pENTR	-	-	-
pFK210B-AtMIR390a-B/c	amiRNA	Spectomycin	BASTA	-	pGreen III	CaMV 35S	rbcS	A. thaliana
pMDC123SB-AtMIR390a-B/c	amiRNA	Kanamycin	BASTA	-	pMDC123	CaMV 2x35S	-	A. thaliana N. benthamiana
pMDC32B-AtMIR390a-B/c	amiRNA	Kanamycin Hygromycin	Hygromycin	-	pMDC32	CaMV 2x35S	nos	A. thaliana N. benthamiana
pENTR-AtTAS1c-B/c	syn-tasiRNA	Kanamycin	-	Donor	pENTR	-	-	-
pMDC123SB-AtTAS1c-B/c	syn-tasiRNA	Kanamycin Hygromycin	BASTA	-	pMDC123	CaMV 2x35S	nos	N. benthamiana
pMDC32B-AtTAS1c-B/c	syn-tasiRNA	Kanamycin Hygromycin	Hygromycin	-	pMDC32	CaMV 2x35S	nos	A. thaliana N. benthamiana